Theradiag SA ALTER.PA Stock
Theradiag SA Price Chart
Theradiag SA ALTER.PA Financial and Trading Overview
| Theradiag SA stock price | 1.26 EUR |
| Previous Close | 2.21 EUR |
| Open | 2.21 EUR |
| Bid | 0 EUR x 0 |
| Ask | 0 EUR x 0 |
| Day's Range | 2.21 - 2.21 EUR |
| 52 Week Range | 1.38 - 2.39 EUR |
| Volume | 65 EUR |
| Avg. Volume | 1.98K EUR |
| Market Cap | 28.8M EUR |
| Beta (5Y Monthly) | -0.290421 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3 EUR |
ALTER.PA Valuation Measures
| Enterprise Value | 24.19M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.1894774 |
| Price/Book (mrq) | 3.4052389 |
| Enterprise Value/Revenue | 1.839 |
| Enterprise Value/EBITDA | 100.213 |
Trading Information
Theradiag SA Stock Price History
| Beta (5Y Monthly) | -0.290421 |
| 52-Week Change | 38.64% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.39 EUR |
| 52 Week Low | 1.38 EUR |
| 50-Day Moving Average | 2.16 EUR |
| 200-Day Moving Average | 2.16 EUR |
ALTER.PA Share Statistics
| Avg. Volume (3 month) | 1.98K EUR |
| Avg. Daily Volume (10-Days) | 1.17K EUR |
| Shares Outstanding | 13.03M |
| Float | N/A |
| Short Ratio | N/A |
| % Held by Insiders | 70.01% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -3.70% |
| Operating Margin (ttm) | -2.11% |
| Gross Margin | 41.48% |
| EBITDA Margin | 1.83% |
Management Effectiveness
| Return on Assets (ttm) | -1.19% |
| Return on Equity (ttm) | -5.61% |
Income Statement
| Revenue (ttm) | 13.16M EUR |
| Revenue Per Share (ttm) | 1.01 EUR |
| Quarterly Revenue Growth (yoy) | 6.20% |
| Gross Profit (ttm) | N/A |
| EBITDA | 241.38K EUR |
| Net Income Avi to Common (ttm) | -487580 EUR |
| Diluted EPS (ttm) | -0.04 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 6.39M EUR |
| Total Cash Per Share (mrq) | 0.49 EUR |
| Total Debt (mrq) | 1.84M EUR |
| Total Debt/Equity (mrq) | 21.76 EUR |
| Current Ratio (mrq) | 3.117 |
| Book Value Per Share (mrq) | 0.649 |
Cash Flow Statement
| Operating Cash Flow (ttm) | N/A |
| Levered Free Cash Flow (ttm) | N/A |
Profile of Theradiag SA
| Country | France |
| State | N/A |
| City | Marne-la-Vallée |
| Address | 14 rue Ambroise Croizat |
| ZIP | 77435 |
| Phone | 33 1 64 62 10 12 |
| Website | https://www.theradiag.com |
| Industry | Medical Devices |
| Sector(s) | Healthcare |
| Full Time Employees | 59 |
Theradiag SA develops, manufactures, and markets in-vitro diagnostic products. It offers LISA tracker, a tool for the monitoring of biotherapies; i-Tracker, a random access solution for therapeutic drug monitoring of biologics; i-Track10 for measurement of drug level and anti-drug antibodies; ez-Track 1 and ez-Tracker, a true point-of-care solution for therapeutic drug monitoring of biologics; and Immunotrol Tracker, a ready-to-use internal quality control sera for pharmacological dosage of biotherapies. The company also provides autoimmune reagents for connective tissue diseases, rheumatoid arthritis, autoimmune liver diseases, vasculitis, celiac disease, anti-phospholipids syndrome, autoimmune thryroiditis, pernicious anemia, and other autoimmune diseases; IMMUNO-TROL, a multi-parametric precision control in autoimmunity; SQA-V system, a semen analyzer; V-Sperm for loading results, pictures, and videos of the samples into the computer; and rapid tests for colorectal cancer. In addition, it offers instrumentation, including FIDIS system for simultaneous and specific detection of multiple analytes from the same sample in a single assay; and Theralis that integrates multiplex FIDIS immunofluorescence and ELISA. The company was founded in 1986 and is based in Marne-la-Vallée, France. Theradiag SA is a subsidiary of Biosynex SA.
Q&A For Theradiag SA Stock
What is a current ALTER.PA stock price?
Theradiag SA ALTER.PA stock price today per share is 1.26 EUR.
How to purchase Theradiag SA stock?
You can buy ALTER.PA shares on the Paris exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Theradiag SA?
The stock symbol or ticker of Theradiag SA is ALTER.PA.
Which industry does the Theradiag SA company belong to?
The Theradiag SA industry is Medical Devices.
How many shares does Theradiag SA have in circulation?
The max supply of Theradiag SA shares is 13.72M.
What is Theradiag SA Price to Earnings Ratio (PE Ratio)?
Theradiag SA PE Ratio is 0.00000000 now.
What was Theradiag SA earnings per share over the trailing 12 months (TTM)?
Theradiag SA EPS is 0 EUR over the trailing 12 months.
Which sector does the Theradiag SA company belong to?
The Theradiag SA sector is Healthcare.